Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen

• Ruth M. de Tute,
• Andy C. Rawstron,
• Walter M. Gregory,
• J. Anthony Child,
• Faith E. Davies,
• Sue E. Bell,
• Gordon Cook,
• Alexander J. Szubert,
• Mark T. Drayson,
• Graham H. Jackson,
• Gareth J. Morgan,
• Roger G. Owen

Affiliations

Ruth M. de Tute

St James’s Institute of Oncology, Leeds, UK

Andy C. Rawstron

St James’s Institute of Oncology, Leeds, UK

Walter M. Gregory

Clinical Trials Research Unit, University of Leeds, UK

J. Anthony Child

Clinical Trials Research Unit, University of Leeds, UK

Faith E. Davies

Institute of Cancer Research, London, UK;University of Arkansas for Medical Sciences, Little Rock, AR, USA

Sue E. Bell

Clinical Trials Research Unit, University of Leeds, UK

Gordon Cook

St James’s Institute of Oncology, Leeds, UK

Alexander J. Szubert

Clinical Trials Research Unit, University of Leeds, UK

Mark T. Drayson

University of Birmingham, UK

Graham H. Jackson

University of Newcastle, UK

Gareth J. Morgan

Institute of Cancer Research, London, UK;University of Arkansas for Medical Sciences, Little Rock, AR, USA

Roger G. Owen

St James’s Institute of Oncology, Leeds, UK